Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 1641: Which class of antibiotics is primarily inactivated by extended-spectrum β-lactamases (ESBLs)?

A. Macrolides
B. Quinolones
C. Aminoglycosides
D. Third-generation cephalosporins (Correct Answer)

Explanation: ***Third-generation cephalosporins*** - **ESBLs** are a group of enzymes primarily known for their ability to hydrolyze and inactivate **third-generation cephalosporins** (e.g., ceftriaxone, ceftazidime) and other beta-lactam antibiotics. - This inactivation mechanism renders agents like **ceftriaxone ineffective** against bacteria producing these enzymes, leading to significant treatment challenges. *Macrolides* - **Macrolides** (e.g., azithromycin, erythromycin) act by **inhibiting bacterial protein synthesis** through binding to the 50S ribosomal subunit. - Their mechanism of action is distinct from beta-lactam antibiotics, and they are generally **not inactivated by ESBL enzymes**. *Quinolones* - **Quinolones** (e.g., ciprofloxacin, levofloxacin) primarily function by **inhibiting bacterial DNA gyrase and topoisomerase IV**, thereby preventing DNA replication. - **ESBLs do not target quinolones**; resistance to quinolones typically arises from mutations in gyrase or efflux pump mechanisms. *Aminoglycosides* - **Aminoglycosides** (e.g., gentamicin, amikacin) are bactericidal antibiotics that **bind to the 30S ribosomal subunit**, interfering with protein synthesis. - While resistance to aminoglycosides can occur through modifying enzymes, **ESBLs do not inactivate this class of antibiotics**.

Question 1642: Which of the following antifungal agents is used in combination therapy for cryptococcal meningitis?

A. Flucytosine (Correct Answer)
B. Nystatin
C. Terbinafine
D. Voriconazole

Explanation: **Flucytosine** - **Flucytosine** is commonly used in combination with **amphotericin B** for the initial treatment of **cryptococcal meningitis** [1][2][3]. - This combination therapy allows for synergy, improving efficacy and potentially reducing the dosage and toxicity of amphotericin B [1]. *Nystatin* - **Nystatin** is an antifungal agent primarily used for topical or oral treatment of **mucocutaneous candidiasis**. - It is not systemically absorbed and therefore ineffective for invasive infections like **cryptococcal meningitis**. *Terbinafine* - **Terbinafine** is an antifungal drug mainly used to treat **dermatophyte infections**, such as athlete's foot and onychomycosis [2]. - Its mechanism of action targets fungal ergosterol synthesis at an early stage, which is not suitable for treating **cryptococcal meningitis**. *Voriconazole* - **Voriconazole** is a broad-spectrum azole antifungal used for severe invasive fungal infections, including **aspergillosis** and **candidiasis** [2]. - While it has some activity against *Cryptococcus*, it is not the preferred or standard agent for initial combination therapy for **cryptococcal meningitis**, for which amphotericin B and flucytosine are typically used [2].

Question 1643: Which oral drug combination is recommended as first-line treatment for uncomplicated malaria caused by chloroquine-resistant P. falciparum?

A. Quinine plus Doxycycline
B. Artemether-Lumefantrine (Correct Answer)
C. Artesunate-Mefloquine
D. Atovaquone-Proguanil

Explanation: ***Artemether-Lumefantrine*** - **Artemether-Lumefantrine (AL)** is a WHO-recommended **Artemisinin-based Combination Therapy (ACT)** and the most widely used first-line treatment for uncomplicated **chloroquine-resistant *P. falciparum* malaria**. - The combination provides **rapid parasite clearance** (artemether) and **prevents recrudescence** (lumefantrine), with excellent efficacy and tolerability. - It is administered as a **3-day oral regimen** and is suitable for use in most endemic regions. *Artesunate-Mefloquine* - While **Artesunate-Mefloquine** is also a WHO-recommended ACT and effective against chloroquine-resistant malaria, it is less commonly used than Artemether-Lumefantrine due to **mefloquine's neuropsychiatric side effects** (dizziness, anxiety, sleep disturbances). - It is primarily used in regions where other ACTs have reduced efficacy, particularly in **Southeast Asia**. *Quinine plus Doxycycline* - **Quinine plus Doxycycline** is an effective combination but is generally considered a **second-line treatment** due to quinine's **poor tolerability** and **complex 7-day dosing regimen**. - **Side effects** include **cinchonism** (tinnitus, headache, nausea) and **cardiac arrhythmias**, limiting its use as first-line therapy. - Doxycycline is contraindicated in **pregnancy** and **children under 8 years**. *Atovaquone-Proguanil* - **Atovaquone-Proguanil (Malarone)** is highly effective and well-tolerated but is **expensive** and primarily used for **prophylaxis** or treatment in **travelers** from non-endemic countries. - It is not recommended as first-line treatment in endemic regions due to **cost considerations** and limited availability.

Question 1644: Which of the following drugs is NOT considered a first-line treatment for candidiasis?

A. Caspofungin (Correct Answer)
B. Nystatin
C. Amphotericin B
D. Fluconazole

Explanation: ***Caspofungin*** - Caspofungin is an **echinocandin** that, while highly effective against *Candida*, is **not typically used as initial therapy** for common candidal infections such as **oral thrush** or **vulvovaginal candidiasis**. - It is generally reserved for **invasive candidiasis** in hospitalized patients or when **azoles are ineffective or contraindicated**. - Its use is limited by **intravenous-only administration**, higher cost, and reserve status for serious infections. *Fluconazole* - **Fluconazole** is the **first-line azole antifungal** for most forms of candidiasis, including **oropharyngeal, esophageal, and vulvovaginal candidiasis**. - Its excellent **oral bioavailability**, favorable side effect profile, and proven efficacy make it the preferred initial treatment in most clinical settings. *Nystatin* - **Nystatin** is a **polyene antifungal** widely used as **first-line therapy** for **localized mucocutaneous candidiasis**, particularly **oral thrush** (as swish-and-swallow suspension) and cutaneous infections. - Its topical action, minimal systemic absorption, and excellent safety profile make it ideal for superficial candidal infections. *Amphotericin B* - **Amphotericin B** is a **broad-spectrum polyene antifungal** with potent fungicidal activity, but it is **not routinely used as first-line therapy** for most candidiasis due to significant toxicity (nephrotoxicity, infusion reactions). - While historically used for severe infections, current guidelines favor **echinocandins or azoles as first-line agents** for invasive candidiasis, with Amphotericin B reserved for resistant cases or specific clinical situations. - Its use as initial therapy is primarily considered when other agents cannot be used due to resistance or contraindications.

Question 1645: Which of the following statements about cephalosporins is false?

A. Active against only gram-positive bacteria (Correct Answer)
B. Ceftriaxone is administered via injection.
C. Bactericidal agents
D. Third-generation cephalosporins are resistant to certain beta-lactamases from gram-negative bacteria.

Explanation: ***Active against only gram-positive bacteria*** - This statement is **false** because later generations of cephalosporins, especially third and fourth generations, have significant activity against **gram-negative bacteria**. - While earlier generations had a stronger gram-positive spectrum, **cephalosporins** as a class are not limited to gram-positive bacteria. *Bactericidal agents* - Cephalosporins are indeed **bactericidal** agents, meaning they kill bacteria rather than just inhibiting their growth. - They achieve this by interfering with **bacterial cell wall synthesis**, specifically by binding to penicillin-binding proteins (PBPs). *Ceftriaxone is administered via injection.* - **Ceftriaxone** is a third-generation cephalosporin commonly administered via **intramuscular or intravenous injection**. - Its long half-life allows for once-daily dosing, making it a convenient option for parenteral treatment. *Third-generation cephalosporins are resistant to certain beta-lactamases from gram-negative bacteria.* - Third-generation cephalosporins were developed to have increased stability against many common **beta-lactamases produced by gram-negative bacteria**, a significant advantage over earlier generations. - This resistance improves their efficacy against a broader range of gram-negative pathogens, although some newer **extended-spectrum beta-lactamases (ESBLs)** can still inactivate them.

Question 1646: Which of the following medications is a first-line antitubercular drug used routinely in children of all age groups without significant monitoring limitations?

A. Ethambutol
B. Streptomycin
C. Pyrazinamide (Correct Answer)
D. Combination of all first-line ATT agents

Explanation: ***Pyrazinamide*** - **Pyrazinamide** is one of the four core first-line antitubercular drugs (along with isoniazid, rifampicin, and ethambutol) [2, 4] and is used **routinely in children of all age groups** without significant monitoring limitations. - It is highly effective against **intracellular mycobacteria** in acidic environments, which are abundant in the early inflammatory stages of tuberculosis [1]. - Its inclusion is crucial for shortening the duration of treatment to 6 months and preventing the development of drug-resistant strains, especially in the initial intensive phase [3, 4]. *Ethambutol* - **Ethambutol** is indeed a first-line antitubercular drug, but its use in **children under 5 years** is often avoided or given with caution due to difficulty in monitoring for **optic neuritis** [1]. - Young children may not be able to reliably report visual changes (color vision defects, decreased visual acuity), making its safe administration challenging [1]. - WHO guidelines recommend avoiding ethambutol in children who cannot reliably report visual symptoms. *Streptomycin* - **Streptomycin** is an **aminoglycoside antibiotic** and is classified as a **second-line** (or alternative first-line) injectable antitubercular drug [3]. - It is primarily used for drug-resistant tuberculosis or in special circumstances where oral first-line regimens cannot be used. - It requires intramuscular injection and is associated with significant toxicities including **ototoxicity** (vestibular and auditory damage) and **nephrotoxicity**, making it unsuitable as a routine first-line option in children. *Combination of all first-line ATT agents* - While the standard treatment involves a **combination of four first-line drugs** (isoniazid, rifampicin, pyrazinamide, and ethambutol), this option describes a treatment regimen rather than answering which individual medication is a first-line drug [3]. - The question specifically asks for "which medication" (singular), making this option inappropriate as an answer.

Question 1647: All are used in the treatment of amoebic liver abscess except:

A. Diloxanide furoate (Correct Answer)
B. Metronidazole
C. Emetine
D. Chloroquine

Explanation: ***Diloxanide furoate*** - This drug is primarily a **luminal amebicide**, meaning it acts in the intestines to eliminate cysts and trophozoites and is used to treat **asymptomatic cyst carriers**. - It is not effective against **extraintestinal forms** of amebiasis, such as an **amebic liver abscess**, where trophozoites are found in tissues. *Metronidazole* - **Metronidazole** is the drug of choice for treating **amebic liver abscess** and other **extraintestinal amebiasis** due to its excellent tissue penetration and amebicidal activity. - It effectively kills **trophozoites** in the liver and other tissues, leading to resolution of the abscess. *Emetine* - **Emetine** (or its derivative, dehydroemetine) is a potent **tissue amebicide** and can be used in the treatment of **amebic liver abscess**, especially when metronidazole is contraindicated or ineffective. - However, its use is limited by significant **cardiotoxicity**, requiring careful monitoring. *Chloroquine* - **Chloroquine** possesses some **amebicidal activity**, particularly against trophozoites in the liver, making it useful as an adjunct or alternative in the treatment of **amebic liver abscess**. - It is often used in combination with other amebicides or in cases where metronidazole alone is insufficient.

Question 1648: Tetracycline is used in prophylaxis of which of the following diseases?

A. Meningitis
B. Leptospirosis (Correct Answer)
C. Brucellosis
D. Cholera

Explanation: ***Leptospirosis (Correct Answer)*** - **Doxycycline**, a tetracycline antibiotic, is the **standard prophylactic agent** for **leptospirosis**, especially for individuals with high exposure risk (travelers to endemic areas, military personnel, occupational exposure). - **Prophylactic regimen**: 200 mg once weekly during exposure and for 2 weeks after last exposure. - It helps prevent the disease by inhibiting bacterial growth before infection becomes established. *Cholera (Incorrect)* - While tetracyclines like doxycycline can be used to **treat cholera** to reduce fluid loss and duration of diarrhea, they are **not used for prophylaxis** in healthy individuals. - Prophylaxis relies on **safe water and sanitation practices**, **oral cholera vaccine**, and proper food handling—not routine antibiotic administration. *Brucellosis (Incorrect)* - **Tetracyclines** (doxycycline) are essential for the **treatment** of **brucellosis**, typically in combination with rifampicin or streptomycin for 6 weeks, due to its intracellular nature and risk of relapse. - However, they are **not routinely used for prophylaxis** against brucellosis, even in high-risk individuals. *Meningitis (Incorrect)* - **Tetracyclines are not recommended for prophylaxis of bacterial meningitis**. - Prophylaxis for close contacts of meningococcal meningitis typically involves **rifampin**, **ceftriaxone**, or **ciprofloxacin**—not tetracyclines.

Question 1649: Which of the following is not typically used as a first-line treatment for Helicobacter pylori infection?

A. Clarithromycin
B. Amoxicillin
C. Metronidazole
D. Ofloxacin (Correct Answer)

Explanation: ***Ofloxacin*** - **Ofloxacin** is a **fluoroquinolone antibiotic** and is generally reserved for **second-line** or **rescue therapies** for *H. pylori* eradication due to increasing resistance and the availability of more established first-line regimens. - While fluoroquinolones can be effective, they are not typically included in standard **triple or quadruple first-line therapies** for *H. pylori* due to concerns about wider antimicrobial resistance and potential side effects when other agents are available. *Clarithromycin* - **Clarithromycin** is a key antibiotic in many **first-line triple therapy regimens** for *H. pylori* eradication, often combined with a proton pump inhibitor and amoxicillin or metronidazole. - Its effectiveness can be limited by regional **clarithromycin resistance rates**, which may necessitate alternative regimens. *Amoxicillin* - **Amoxicillin** is a commonly used antibiotic in **first-line triple therapy** for *H. pylori*, typically combined with a proton pump inhibitor and clarithromycin. - It is generally well-tolerated and effective, particularly in areas with lower rates of amoxicillin resistance. *Metronidazole* - **Metronidazole** is an important component of several **first-line *H. pylori* eradication regimens**, including classic triple therapy (when amoxicillin is not used) and bismuth-based quadruple therapy. - Its use depends on local **metronidazole resistance patterns** and patient tolerance, as some individuals experience side effects like a metallic taste or nausea.

Question 1650: A patient with a confirmed infection by ESBL-producing Klebsiella pneumoniae is being treated with ceftriaxone. What modification is needed in his antibiotic treatment?

A. Replace ceftriaxone with a fluoroquinolone
B. Continue the same antibiotics at higher doses
C. Replace ceftriaxone with imipenem (Correct Answer)
D. Replace ceftriaxone with ceftazidime

Explanation: ***Replace ceftriaxone with imipenem*** - **ESBL-producing organisms** (Extended-Spectrum Beta-Lactamase) are resistant to **third-generation cephalosporins** like ceftriaxone [1]. - **Carbapenems**, such as imipenem, are generally the drugs of choice for serious infections caused by ESBL-producing bacteria due to their broad spectrum and stability against ESBL enzymes. *Replace ceftriaxone with a fluoroquinolone* - While fluoroquinolones are broad-spectrum antibiotics, resistance in **Klebsiella pneumoniae** is increasing, and they are not reliably effective against ESBL-producing strains. - Using a fluoroquinolone for a confirmed ESBL infection without susceptibility data could lead to treatment failure and increased resistance. *Continue the same antibiotics at higher doses* - **Ceftriaxone** is a beta-lactam antibiotic that is destroyed by **ESBL enzymes**, rendering it ineffective regardless of the dose. - Increasing the dose of an ineffective antibiotic will not overcome the resistance mechanism and may lead to increased toxicity without clinical benefit. *Replace ceftriaxone with ceftazidime* - **Ceftazidime** is also a **third-generation cephalosporin** and is susceptible to degradation by ESBL enzymes. - Switching from one third-generation cephalosporin to another will not address the underlying **ESBL resistance mechanism**.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free